Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a Presentation. TAIPEI, Taiwan, ...

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Dr. Heidi Wang Accepts Award on Behalf of OBI Pharma at ADC Asia Congress 2025 and Gives a PresentationTAIPEI, Taiwan, March 12, 2025 (GLOBE NEWSWIRE) -- At the ADC Asia Congress 2025 held today (3/12 ...

The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

For many of these conditions, women present later and sicker, and are less likely to be treated appropriately.

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...

With the changing nature of aviation in the face of advanced air mobility, it is important that future generations be engaged ...

Cancer clusters haunt a creosote-contaminated rail yard in Houston's Fifth Ward. But if there's no ongoing harm, will the ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...